600267 Zhejiang Hisun Pharmaceutical
- 8.56
- -0.14-1.61%
Zhejiang Hisun Pharmaceutical News
Haizheng Pharmaceutical (600267.SH): In terms of synthetic biology, results have been achieved in improving the production level of core strains through gene editing technology
Gelonghui, May 10, 丨 Haizheng Pharmaceutical (600267.SH) said on the interactive platform that in terms of synthetic biology, the company achieved results in improving the production level of core strains through gene editing technology; at the same time, it uses yeast, Escherichia coli, Corynebacterium glutamate, etc. to lay out raw materials such as new materials, functional foods, and functional skincare products; the enzyme catalytic technology platform has approved a raw material with a full enzymatic process, and is also developing multiple pharmacological intermediate processes, focusing on targeted screening of transaminases, redoxases, transferases, and ligases.
Haizheng Pharmaceutical (600267.SH): Existing varieties of orlistat in the field of diet pills
Gelonghui, May 10 | Haizheng Pharmaceutical (600267.SH) said on an interactive platform that the company currently has a variety of orlistat in the field of diet pills.
Haizheng Pharmaceutical: “Haizheng Dingzhan” can choose to resell
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that the closing price of the company's stock for 30 consecutive trading days from March 18, 2024 to April 30, 2024 was lower than 80% of the current share conversion price of the company's “Haizheng Transfer”. According to the agreement in the “Transaction Report”, the “Haizheng Ding Transfer” resale clause came into effect.
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Haizheng Pharmaceutical (600267.SH) announced first-quarter results, net profit of 249 million yuan, up 6.99% year on year
According to the Zhitong Finance App, Haizheng Pharmaceutical (600267.SH) released its report for the first quarter of 2024, with revenue of 2,727 billion yuan, a year-on-year decrease of 11%. Net profit attributable to shareholders of listed companies was 249 million yuan, an increase of 6.99% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 133 million yuan, a year-on-year decrease of 21.32%. Basic earnings per share were $0.21.
Express News | Haizheng Pharmaceutical invests in innovative drug research enterprise Vanosi
Haizheng Pharmaceutical (600267.SH): Completed the repurchase and actually repurchased 0.97% of the company's shares
Gelonghui, April 19, 丨 Haizheng Pharmaceutical (600267.SH) announced that on April 18, 2024, the company's third share repurchase plan was completed. It actually repurchased 11.6872 million shares, accounting for 0.97% of the company's total share capital. The highest repurchase price was 9.75 yuan/share, the lowest repurchase price was 7.17 yuan/share, the average repurchase price was 8.47 yuan/share, and the total capital used was 98.99.27 million yuan (excluding transaction fees).
Hisun Pharma's Unit Gets Nod for Pig Vaccine
Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Yunnan Biopharmaceutical, received approval for a pig vaccine from China's Ministry of Agriculture and Rural Affairs, the pharmaceutical company said
Haizheng Pharmaceutical: No downward revisions to the “Haizheng Dingzheng Transfer” share conversion price
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that as of April 15, 2024, the company will trigger a downward revision of the “Haizheng Transfer” share conversion price. After deliberation and approval at the 26th meeting of the 9th board of directors of the company, the board of directors of the company decided not to exercise the right to revise the “Haizheng Transfer” share conversion price downward, and that within the next 12 months (April 16, 2024 to April 15, 2025), if once again triggering the terms of downward revision of the conversion price of convertible corporate bonds (hereinafter referred to as “convertible bonds”), it will not propose a downward correction plan.
Haizheng Pharmaceutical (600267.SH): It has repurchased a total of 7.829,900 shares at a cost of 697.16,300 yuan
Gelonghui, April 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of March 31, 2024, the company had repurchased a total of 7.829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 697.16,300 yuan (excluding transaction fees).
Further Weakness as Zhejiang Hisun Pharmaceutical (SHSE:600267) Drops 5.0% This Week, Taking Three-year Losses to 46%
Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Zhitong A Share Sale Restriction and Release List | March 25
According to the Zhitong Finance App, the ban on restricted shares of 18 listed companies was lifted on March 25, with a total market value of about 23.024 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted share type, number of unbanned shares Zotye Auto 000980 additional A shares, corporate placement, listing 471 million, Haizheng Pharmaceutical 600267, corporate placement, listing 599315 Wan Aixu shares 600732 share incentives limited sale and circulation 3308 million Ruifeng Bank 601,528 shares restricted circulation before issuance, 9897 thousand Muyuan shares 002714 share incentives limited sale and circulation 2515
Haizheng Pharmaceutical (600267.SH): 59.315 million restricted shares will be listed and circulated on March 25
Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company's current stock listing type is non-public shares; the stock subscription method is offline, and the total number of shares currently in circulation is 599.315 million shares. The current stock listing circulation date is March 25, 2024.
Retail Investors Are Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Biggest Owners and Were Hit After Market Cap Dropped CN¥488m
Key Insights Significant control over Zhejiang Hisun Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions The to
Haizheng Pharmaceutical (600267.SH): A total cost of 697.16 million yuan to buy back 0.6482% of shares
Gelonghui, March 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of February 29, 2024, the company had repurchased a total of 7,829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 69,716,268.41 yuan.
Haizheng Pharmaceutical (600267.SH): Oseltamivir phosphate API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”
Gelonghui, Feb. 28: Haizheng Pharmaceutical (600267.SH) announced that Haizheng Pharmaceutical Nantong Co., Ltd., a wholly-owned subsidiary, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for oseltamivir phosphate APIs approved and issued by the State Drug Administration on February 28, 2024. Oseltamivir phosphate is a precursor drug for its active metabolite (oseltamivir carboxylate). Oseltamivir carboxylate is a selective influenza virus neuraminidase inhibitor used in the treatment of influenza A and B in adults and children aged 1 year and over, as well as influenza A and B in adults and adolescents aged 13 and over
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
The Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) share price has fared very poorly over the last month, falling by a substantial 27%. The drop over the last 30 days has capped off a tough
Haizheng Pharmaceutical (600267.SH): A total cost of 568.487 million yuan to buy back 0.5% of shares
Gelonghui, January 31, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of January 31, 2024, the company had repurchased a total of 6,111,900 shares, accounting for 0.5060% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.71 yuan/share, and the total amount paid was 56,848,689.65 yuan.
Zhitong A Share Sale Restriction and Release List | January 31
According to the Zhitong Finance App, the ban on restricted shares of 9 listed companies was lifted on January 31, with a total market value of about 9.153 billion yuan. Today's specific sales restrictions have been lifted as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Haizheng Pharmaceutical's 600267 debt-for-share transfer, restricted circulation 39, Aerospace Electronics 600879, original shareholder placement 510 million, Bank of Chengdu 601,838 shares limited sale and circulation 737,700 Jinguiyin 002716 extends sales restrictions and regular circulation of 5.3363 million Leon Technology 300603 A-shares, corporate distribution and listing of 1.718,000 Qingdao Food
Haizheng Pharmaceutical (600267.SH) forecasted a net loss of 65 million to 95 million yuan in 2023, from profit to loss year-on-year
Haizheng Pharmaceutical (600267.SH) disclosed the 2023 annual results pre-loss announcement. The company expects to belong during the reporting period...
Analysis
Price Target
No Data
